Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.

@article{Kris1988DoserangingEO,
  title={Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.},
  author={Mark G. Kris and Richard J. Gralla and Rebecca Adair Clark and Leslie B. Tyson},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1988},
  volume={6 4},
  pages={659-62}
}
GR-C507/75 (GR38032F) antagonizes the 5-HT3 (serotonin) receptor and prevents cisplatin-induced emesis in animals. In this dose-ranging trial, 44 patients with cancer receiving chemotherapy known to produce nausea and vomiting (including cisplatin, cyclophosphamide, and doxorubicin) received three intravenous (IV) infusions of GR-C507/75 every two hours… CONTINUE READING